Introduction
============

The link between coagulation and malignancy has been recognized for over a century. [@JR170005-1] [@JR170005-2] Thrombosis is a common cause of death in cancer patients. Pulmonary embolism (PE) was more commonly detected in cancer patients at autopsy than in those without malignancy. [@JR170005-3] PE may also be the presenting signs of an underlying occult malignancy. [@JR170005-4] In addition, it is accepted that coagulation activation and platelet activation in the tumor microenvironment may have a biological significance affecting tumor growth and dissemination (or metastasis).

Cutaneous melanoma is a common skin cancer with an incidence rate of 14.1 per 100,000 inhabitants per year, [@JR170005-5] arising from the pigment-containing cells known as melanocytes. Ultraviolet radiation from sunlight or tanning devices can induce malignant transformation of these cells by inducing DNA damage, especially in fair-skinned individuals. In addition to the environmental factors, genetics and/or immune status may also play a role in the malignant transformation. When mutations persist in proto-oncogenes, an uncontrolled rate of mitosis could lead to cell transformation and tumor formation. The levels of activating transcription factors in the nucleus of melanoma-inducing cells are associated with increased metastatic activity. [@JR170005-6] If early diagnosis is made, surgical excision is curative. However, once it metastasizes, the prognosis can be dismal, because metastatic melanoma does not response to chemotherapy, immunologic therapy, or radiotherapy. [@JR170005-7]

Previous studies have demonstrated that VWF, FVIII, platelets, and other procoagulants, such as tissue factor, factor X, and thrombin, may not only result in the development of deep vein thromboembolism, but may also be associated with metastasis of malignant melanoma. [@JR170005-8] [@JR170005-9] Plasma levels of VWF antigen are elevated in patients with metastatic melanoma, primarily resulting from activation of endothelium. [@JR170005-10] Depending on the experimental model, *vwf* -deficient mice are reported to exhibit either significantly increased or reduced metastatic potential. [@JR170005-11] [@JR170005-12] Analysis of blood samples of metastatic melanoma patients demonstrated that increased plasma levels of procoagulant proteins such as VWF [@JR170005-13] and vascular endothelial growth factor A (VEGF-A) [@JR170005-13] and decreased expression or ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats 13) activity create an environment that promotes tumor-associated thrombosis. [@JR170005-13]

FVIII is an important procoagulant protein that binds to VWF with high affinity. In the coagulation cascade, thrombin activates FVIII to form FVIIIa, which dissociates from VWF and acts as a cofactor for factor IXa to activate factor X, which then activates prothrombin to form more thrombin. Thrombin cleaves fibrinogen to fibrin, which stabilizes platelets and clots. [@JR170005-14] Previous studies have demonstrated the association between baseline plasma FVIII activity in cancer patients, specifically in those with breast, colorectal, and cutaneous malignancies. [@JR170005-15] [@JR170005-16] However, the association between the genetic alterations in the gene encoding *FVIII* , *VWF* , and *ADAMTS13* and long-term outcomes in patients with cutaneous melanoma has not been investigated in a large cohort of datasets.

This article takes advantage of the recent whole exome sequence (WES) datasets, mRNA expression (RNA-seq) data, and bioinformatics tools to determine the prognostic value of somatic mutations in *FVIII* , *VWF* , and *ADAMTS13* in cutaneous melanoma. Our results demonstrate that somatic mutations in *FVIII* , but not in *VWF* and *ADAMTS13* , are associated with a more favorable survival outcome. Further investigation of the molecular mechanism underlying how *FVIII* mutations are associated with a better outcome will help understand the pathogenesis of cutaneous melanoma, which may lead to the development of a novel therapeutic for such malignancy.

Materials and Methods
=====================

Data Mining with cBioPortal and TCGA Browser v0.9
-------------------------------------------------

Using cBioPortal, cross cancer studies were first performed to identify cancer studies with the highest mutation rates within *FVIII* , *VWF* , and *ADAMTS13* genes. Since the top-5 identified studies were all melanoma-related projects from different institutions, we focused on analyzing these three genes in melanoma datasets. All searches were performed according to cBioPortal\'s online instructions ( <http://www.cbioportal.org/index.do> ). The survival analysis related to mRNA expression of *VWF* was performed on the TCGA Browser 0.9 from the University Hospital Zurich ( <http://tcgabrowser.ethz.ch:3839/TEST/> ). The mRNA expression of *VWF* was ranked from high to low, and the top one-third cases were defined as "high *VWF* ," while the bottom one-third of cases were defined as "low *VWF* ."

Melanoma Datasets for Analyses and Validation
---------------------------------------------

As of June 4, 2017, the cBioPortal includes five melanoma datasets. The provisional "TCGA skin cutaneous melanoma" is the largest one with a total of 479 samples. Of these, 113 cases without mutation data were excluded from our study and the remaining 366 cases were used for further analyses. The corresponding clinical and pathological information associated with the patients in this dataset was downloaded from both the NCI\'s Genomic Data Commons ( <https://gdc-portal.nci.nih.gov/> ) and the cBioPortal. The data from the two sources were compared to ensure that the most up-to-date clinical and pathological information was used for this analysis. The mutation pattern in *FVIII* , *VWF* , and *ADAMTS13* genes was found to be similar in the second cohort of 121 Broad patients [@JR170005-17] and the third cohort of 91 Yale melanoma patients. [@JR170005-18]

Selection of the Melanoma Diagnostic Features
---------------------------------------------

The pathologic criteria used to determine any correlation with the mutations were based on the current WHO classification of human cutaneous melanoma and the AJCC cancer staging manual, 7th edition, including tumor depth (Clark\'s level and Breslow\'s thickness), tumor size, tumor site, lymph node, and metastasis status.

Statistical Analysis
--------------------

Clinical and pathological predictors in this study are listed in [Table 1](#TB170005-1){ref-type="table"} . The primary outcome is the mortality rate. Fisher\'s exact test was used to compare the categorical variables between the group with *FVIII* mutations and those without *FVIII* mutations. The Student *t* -test was used to compare the continuous variables between the subgroups. Univariate analysis was performed using the log-rank test to correlate each clinical and pathological predictor with survival outcome. All tests were performed using the XLSTAT version 2014 (Addinsoft XLSTAT, France). All *p* -values were nonpaired and two sided. *p* -Values less than 0.05 and 0.01 are considered to be statistically significant and highly significant, respectively.

###### Patient characteristics of categorical variables in *FVIII* -mutated and *FVIII* nonmutated groups

  Variable                                                   Categories           *FVIII* nonmutated ( *n*  = 312)   *FVIII* mutated ( *n*  = 54)   *p* -Value               
  ---------------------------------------------------------- -------------------- ---------------------------------- ------------------------------ ------------ ----------- -----------
  Gender                                                     Female               118                                37.8                           22           40.7        0.835
  Male                                                       194                  62.2                               32                             59.3         0.835       
  Race                                                       Asian                9                                  2.9                            1            1.9         0.641
  Black                                                      1                    0.3                                0                              0.0          0.671       
  While                                                      301                  96.5                               52                             96.3         0.207       
  Unknown                                                    1                    0.3                                1                              1.9                      
  Tumor site                                                 Distant metastasis   6                                  1.9                            0            0.0         0.295
  Extremities                                                134                  42.9                               20                             37.0         0.312       
  Head and neck                                              22                   7.1                                6                              11.1         0.341       
  Regional cutaneous [a](#FN170005-3){ref-type="table-fn"}   3                    1.0                                4                              7.4          **0.002**   
  Regional lymph node                                        18                   5.8                                5                              9.3          0.368       
  Trunk                                                      118                  37.8                               18                             33.3         0.418       
  Unknown                                                    11                   3.5                                1                              1.9          N/A         
  Current tumor status                                       **Tumor free**       **138**                            **44.2**                       **33**       **61.1**    **0.042**
  **With tumor**                                             **157**              **50.3**                           **18**                         **33.3**     **0.012**   
  Unknown                                                    17                   5.4                                3                              5.6          N/A         
  Clark level at diagnosis                                   I                    5                                  1.6                            0            0.0         0.340
  II                                                         13                   4.2                                2                              3.7          0.836       
  III                                                        51                   16.3                               9                              16.7         0.959       
  IV                                                         113                  36.2                               18                             33.3         0.558       
  V                                                          40                   12.8                               3                              5.6          0.109       
  Unknown                                                    90                   28.8                               22                             40.7         N/A         
  Primary melanoma ulceration                                No                   104                                33.3                           16           29.6        0.484
  Yes                                                        123                  39.4                               17                             31.5         0.198       
  Unknown                                                    85                   27.2                               21                             38.9         N/A         
  T                                                          T0                   15                                 4.8                            7            13.0        **0.025**
  Tis                                                        7                    2.2                                0                              0.0          0.258       
  T1                                                         24                   7.7                                5                              9.3          0.752       
  T2                                                         57                   18.3                               9                              16.7         0.693       
  T3                                                         63                   20.2                               6                              11.1         0.094       
  T4                                                         102                  32.7                               15                             27.8         0.382       
  TX                                                         44                   14.1                               12                             22.2         N/A         
  N                                                          N0                   149                                47.8                           31           57.4        0.295
  N1                                                         54                   17.3                               7                              13.0         0.373       
  N2                                                         36                   11.5                               7                              13.0         0.837       
  N3                                                         41                   13.1                               4                              7.4          0.207       
  NX                                                         32                   10.3                               5                              9.3          N/A         
  M                                                          M0                   275                                88.1                           51           94.4        0.806
  **M1** [b](#FN170005-4){ref-type="table-fn"}               **21**               **6.7**                            **0**                          **0.0**      **0.046**   
  MX                                                         16                   5.1                                3                              5.6          N/A         
  Stage                                                      Stage 0              6                                  1.9                            0            0.0         0.295
  Stage I                                                    50                   16.0                               10                             18.5         0.733       
  Stage II                                                   80                   25.6                               16                             29.6         0.646       
  I/II/not sure                                              6                    1.9                                4                              7.4          0.027       
  Stage III                                                  125                  40.1                               18                             33.3         0.263       
  Stage IV                                                   18                   5.8                                1                              1.9          0.215       
  Unknown                                                    27                   8.7                                5                              9.3          N/A         
  Postoperative chemotherapy                                 No                   210                                67.3                           44           81.5        0.093
  Yes                                                        62                   19.9                               6                              11.1         0.104       
  Unknown                                                    40                   12.8                               4                              7.4          N/A         
  Postoperative radiation                                    No                   287                                92.0                           50           92.6        0.503
  Yes                                                        16                   5.1                                4                              7.4          0.540       
  Unknown                                                    9                    2.9                                0                              0.0          N/A         

Abbreviations: M, distant metastases; N, lymph node; N/A, not determined; T, tumor; X after T, N, M indicates unknown status.

Values in bold indicate the difference between the two groups is statistically significant with *p*  \< 0.05.

This category includes satellite and in-transit metastasis.

All 21 metastatic cases were found in the *FVIII* nonmutated group.

Results
=======

Mutations in FVIII, VWF, and ADAMTS13 in Various Malignant Neoplasms
--------------------------------------------------------------------

The cBioPortal database has collected a large group of cancer genomic sequencing data. As of June 4, 2017, there were 25,719 samples from 126 cancer studies. In all cancer studies, the mutations in *FVIII* , *VWF* , and *ADAMTS13* were reported in 93 cancer studies. The top-5 studies were all melanoma studies from different institutions with the mutation rates ranging from 24 to 50%. [@JR170005-18] [@JR170005-19] High mutation rates in *FVIII* , *VWF* , and *ADAMTS13* were also reported in diffuse large B cell lymphoma (22.9%), small cell lung carcinoma (20.7%), cholangiocarcinoma (20.0%), and colorectal adenocarcinoma (19.4%; [Fig. 1](#FI170005-1){ref-type="fig"} ).

![Top-10 cancer studies show the highest mutation rates in genes encoding *FVIII* , *VWF* , and *ADAMTS13* . The rates of *FVIII* , *VWF* , and *ADAMTS13* mutations were obtained by searching database among 126 cancer studies using cBioPortal. Each bar represents the percentage of mutation found in all three genes (e.g., *FVIII* , *VWF* , and *ADAMTS13* ) in each individual study.](10-1055-s-0037-1607337-i170005-1){#FI170005-1}

Characteristics of Patients with or without FVIII Mutations
-----------------------------------------------------------

In the provisional "TCGA skin cutaneous melanoma" dataset, 54 patients had *FVIII* mutations and 312 patients had no *FVIII* mutation. All mutations found by WES were confirmed by RNA-seq in the same specimen, which were not present in the genomic DNA isolated from the patient leukocytes. [@JR170005-17] [@JR170005-19] No significant difference was identified between patient\'s age, gender, Clark\'s level, Breslow\'s thickness, primary tumor ulceration, lymph node status, stage, overall copy number variation, and the percentage of postoperative chemo/radiation therapy in melanoma patients with and without *FVIII* mutations except for mutations counts ( [Table 1](#TB170005-1){ref-type="table"} and [Supplementary Table 1](#SM170005-1){ref-type="supplementary-material"} ). However, Fisher\'s exact test demonstrated that all 21 cases (6.7%) with metastasis were all reported in the *FVIII* nonmutated group, but no metastatic case (0%) was reported in the *FVIII* -mutated group ( *p*  = 0.046). Furthermore, patients with the *FVIII* mutation are more likely to be in the tumor-free group (61.1 vs. 44.2%, *p*  = 0.042; [Table 1](#TB170005-1){ref-type="table"} ). Interestingly, the overall mutation counts were also significantly higher in the *FVIII* -mutated group than in the *FVIII* nonmutated group ( *p*  = 0.013; [Supplementary Table 1](#SM170005-1){ref-type="supplementary-material"} ).

Mutation Profiles in FVIII, VWF, and ADAMTS13 in Cutaneous Melanoma
-------------------------------------------------------------------

Among five melanoma studies, the provisional "TCGA skin cutaneous melanoma" project was the largest one with sequencing data from 479 samples. This was also the only cohort with corresponding pathological and clinical information described earlier for each patient. The mutation rates in *FVIII* , *VWF* , and *ADAMTS13* from the TCGA provisional datasets were 15, 14, and 5%, respectively ( [Fig. 2A](#FI170005-2){ref-type="fig"} ). Similar results were obtained from other two datasets: 121 Broad patients ( [Fig. 2B](#FI170005-2){ref-type="fig"} ) [@JR170005-17] and 91 Yale patients [@JR170005-18] ( [Fig. 2C](#FI170005-2){ref-type="fig"} ). A majority of mutations identified were missense and nonsense resulting in amino acid changes and a truncation of FVIII protein, respectively. The number of mutations in *FVIII* , *VWF* , and *ADAMTS13* appeared to directly correlate with the length of coding regions of the genes ( *r* ^2^  = 0.993). However, there was no evidence of a mutational hotspot in any of these three genes ( *FVIII* , *VWF* , and *ADAMTS13* ; [Fig. 3](#FI170005-3){ref-type="fig"} ). All these gene mutations found by WES were verified with the RNA-Seq analysis in the same tumor samples, which were not present in the genomic DNA isolated from leukocytes of the patients. [@JR170005-17] [@JR170005-18] [@JR170005-19] These results suggest the somatic mutation, rather than inherited. These mutated gene products were expressed in the tumor cells. Furthermore, there was a strong tendency of coexistence of mutations in both *FVIII* and *VWF* or in both *VWF* and *ADAMTS13* in a single patient (not shown).

![Mutation profiles of *FVIII, VWF* , and *ADAMTS13* found in cutaneous melanoma of three datasets. ( **A** ) TCGA provisional; ( **B** ) broad cell, 2012; and ( **C** ) Yale Nature Genetics, 2012.](10-1055-s-0037-1607337-i170005-2){#FI170005-2}

![Detailed mutation maps of *FVIII* , *VWF* , and *ADAMTS13* found in patients with cutaneous melanoma. Each dot above the protein molecule represents a mutation, which spreads across the entire encoded protein of FVIII ( **A** ), VWF ( **B** ), and ADAMTS13 ( **C** ). There is no evidence of a "hotspot" of gene mutations.](10-1055-s-0037-1607337-i170005-3){#FI170005-3}

Effect of Somatic Mutations in FVIII, VWF, and ADAMTS13 on the Overall Survival of Melanoma Patients
----------------------------------------------------------------------------------------------------

Log-rank test showed that mutations in *FVIII* ( [Fig. 4A](#FI170005-4){ref-type="fig"} ), but not in *VWF* ( [Fig. 4B](#FI170005-4){ref-type="fig"} ) and *ADAMTS1* 3 ( [Fig. 4C](#FI170005-4){ref-type="fig"} ), were significantly associated with a better survival rate in melanoma patients. In addition, no association was found between the combined mutations of *VWF* , *FVIII* , and *ADAMTS13* with the long-term survival rate ( [Fig. 4D](#FI170005-4){ref-type="fig"} ). Interestingly, low *VWF* , but not *FVIII* and *ADAMTS13* , mRNA expression in the melanoma tissue itself was associated with a better overall survival rate ( *p*  = 0.02; [Fig. 4E](#FI170005-4){ref-type="fig"} ), suggesting that the decreased *VWF* gene expression in association with *FVIII* mutations may have a protective effect in patients with melanoma. Specifically, patients with the *FVIII* mutations had a median survival of 269 months compared with the median survival of 67 months in those without the *FVIII* mutations ( *p*  = 0.02).

![Association of mutations in *FVIII* , *VWF* , and *ADAMTS13* and their expression levels with the long-term outcomes of cutaneous melanoma. ( **A** ) *FVIII* mutations are associated with a better overall survival rate ( *p*  = 0.02). ( **B** and **C** ) *VWF* and *ADAMTS13 (AT13)* mutations are not associated with a better overall survival rate ( *p*  = 0.42 and *p*  = 0.90, respectively). ( **D** ) Combined mutations of *VWF* / *FVIII* / *AT13* are not associated with an overall survival rate ( *p*  = 0.24). ( **E** ) Low *VWF* mRNA expression is associated with a better survival rate ( *p*  = 0.04).](10-1055-s-0037-1607337-i170005-4){#FI170005-4}

The Effect of Mutations on mRNA and Protein Expressions of FVIII, VWF, and ADAMTS13 in Melanoma Patients
--------------------------------------------------------------------------------------------------------

To investigate the possible underlying mechanism of the protective role of *FVIII* mutations in patients with cutaneous melanoma, we tested the effect of mutations in *FVIII* , *VWF* , and *ADAMTS13* on mRNA expression based on the RNA-Seq data. As shown, *FVIII* mutations did not result in a significant alteration of *VWF* ( [Fig. 5A](#FI170005-5){ref-type="fig"} ) and *ADAMTS13* mRNA expression ( [Fig. 5B](#FI170005-5){ref-type="fig"} ), but they did significantly lower the *FVIII* mRNA expression ( *p*  \< 0.001) as one might anticipate ( [Fig. 5C](#FI170005-5){ref-type="fig"} ). We further tested the entire mRNA expression profile in the tumor tissue from patients with *FVIII* mutations. Using both *p* -value (Student\'s *t* -test) and Q-value (false discovery rate) less than 0.05 as the inclusion criteria, we identified a total of 44 genes with a significant difference between those with the *FVIII* mutations and those without ( [Supplementary Table 2](#SM170005-1){ref-type="supplementary-material"} ). A total of 38 genes showed an increased expression of mRNA in the *FVIII* -mutated group and 6 genes, including *VWF* , showed decreased mRNA expression in *FVIII* -mutated group compared with *FVIII* nonmutated group ( [Supplementary Table 2](#SM170005-1){ref-type="supplementary-material"} ).

![Association between mutations in *FVIII* and expression of *VWF* , *FVIII* , and *ADAMTS13* mRNA in patients with cutaneous melanoma. The levels of mRNA expression (mean ± 95% confidential interval) for *VWF* ( **A** ), *FVIII* ( **B** ), and *ADAMTS13* ( **C** ) in patients with or without *FVIII* mutations. ( **D** ). Hematoxylin and eosin staining (i and ii) and immunohistochemistry with rabbit anti-VWF IgG (iii and iv), sheep anti-FVIII IgG (v and vi), and rabbit anti-ADAMTS13 IgG (vii and viii), followed by streptavidin-peroxidase conjugated anti-rabbit IgG or anti-sheep IgG or secondary antibody only (ix and x).](10-1055-s-0037-1607337-i170005-5){#FI170005-5}

VWF is produced in all vascular endothelium; FVIII is expressed only in the sinusoidal and pulmonary vascular endothelium; ADAMTS13 is primarily synthesized in hepatic stellate cells, [@JR170005-20] but also found in trace amount in the vascular endothelium [@JR170005-21] [@JR170005-22] and platelets. [@JR170005-23] While *VWF* , *FVIII* , and *ADAMTS13* mRNAs were identified in the melanoma tissues through RNA-Seq analysis, the protein expression has never been examined in tumor tissues. We set to determine the protein expression in seven melanoma cases by immunohistochemistry. The results showed that VWF ( [Fig. 5D](#FI170005-5){ref-type="fig"} , iii and iv) and FVIII ( [Fig. 5D](#FI170005-5){ref-type="fig"} , v and vi) were not detected in the melanoma cells, but ADAMTS13 immune reactivity was strongly positive in melanoma cells ( [Fig. 5D](#FI170005-5){ref-type="fig"} , vii and viii). Control staining was negative when primary antibodies were omitted ( [Fig. 5D](#FI170005-5){ref-type="fig"} , ix and x). The specific VWF staining was detected in the vascular endothelium within the melanoma tissues ( [Fig. 5D](#FI170005-5){ref-type="fig"} , iii and iv, arrowheads). These results demonstrate that while mRNAs for *VWF* , *FVIII* , and *ADAMTS13* are all expressed in melanoma tissue, the protein concentrations of VWF and FVIII, but not ADAMTS13, in the tumor tissues may be quite low.

Discussion
==========

This study highlights the high mutation rates in genes encoding *FVIII* , *VWF* , and *ADAMTS13* in patients with metastatic cutaneous melanoma ( [Figs. 1](#FI170005-1){ref-type="fig"} [2](#FI170005-2){ref-type="fig"} [3](#FI170005-3){ref-type="fig"} ). The presence of mutations in *FVIII* , but not in *VWF* and *ADAMTS13* or a combined mutation rate of *FVIII, VWF* , and *ADAMTS13* , is associated with a more favorable overall survival in these patients ( [Fig. 4](#FI170005-4){ref-type="fig"} ). The results suggest that the mutation burden in *FVIII* may be useful as a prognostic marker. These results may also suggest a potential role of FVIII protein and its carrier protein VWF in the pathobiology of melanoma including tumor growth and metastasis by affecting the tumor microenvironment.

As shown in our data, patients with the *FVIII* mutations exhibited significantly lower expression of the *FVIII* mRNA, which may be translated with the reduced levels of FVIII procoagulant activity in situ around the tumors ( [Fig. 5](#FI170005-5){ref-type="fig"} ), although immunohistochemical studies did not detect the FVIII protein in all seven cases of melanoma ( [Fig. 5](#FI170005-5){ref-type="fig"} and [Table 2](#TB170005-2){ref-type="table"} ). This may be caused by the low abundance of FVIII protein in any given cell. Further determination of FVIII synthesis and secretion from cultured melanoma cells with or without *FVIII* mutations may help better understand the pathophysiological relevance of the *FVIII* mutations.

###### Expression of VWF, FVIII, and ADAMTS13 in melanoma tissues by immunohistochemistry

  Case no.   Age at diagnosis (y)   Gender   Diagnosis            Location               Clark level   Breslow depth   Melanoma         
  ---------- ---------------------- -------- -------------------- ---------------------- ------------- --------------- ---------- ----- -------
  1          85                     Male     Recurrent melanoma   Face                   N/A           N/A             (−)        (−)   (+++)
  2          63                     Female   Melanoma             Right arm              N/A           N/A             (−)        (−)   (−)
  3          69                     Female   Invasive melanoma    Left thigh             III           0.8 mm          (−)        (−)   (++)
  4          35                     Female   Invasive melanoma    Left abdomen           II            0.38 mm         (−)        (−)   (+)
  5          64                     Female   Melanoma             Right parietal scalp   V             4.15 mm         (−)        (−)   (++)
  6          84                     Male     Invasive melanoma    Left cheek             III           0.45 mm         (−)        (−)   (++)
  7          67                     Male     Invasive melanoma    Right lateral chest                  0.65 mm         (−)        (−)   (++)

Abbreviations: ADATMS13, a disintegrin and metalloprotease with thrombospondin type 1 repeats 13; FVIII, factor VIII; N/A, not available; VWF, von Willebrand factor.

Note: −, +, ++, and +++ denote negative, mild, moderate, and strong positive in staining on tumor cells. VWF antibody stained all vessels.

The role of FVIII in melanoma biology has been previously investigated in animal studies. Hemophilia A mice lacking plasma FVIII activity were protective against the formation of lung metastatic foci after an intravenous inoculation of a murine melanoma cell line (B16F10). [@JR170005-24] [@JR170005-25] A single-dose infusion of human FVIII (100 U/kg) into hemophilia A mice significantly enhanced the lung metastasis of murine melanoma cells. [@JR170005-25] In contrast, administration of a factor Xa inhibitor (i.e., tinzaparin) to wild-type mice [@JR170005-26] or a direct thrombin inhibitor (i.e., lepirudin or argatroban) into wild-type mice [@JR170005-27] and hemophilia A mice [@JR170005-24] [@JR170005-25] significantly reduced lung metastasis, suggesting that thrombin generation in the presence or absence of FVIII contributes to pulmonary metastasis. Thrombin is known to support tumor spreading and metastasis, predominantly mediated by the cleavage of a protease-activated receptor-1 (PAR-1), which is highly expressed on the surface of platelets, endothelial cells, and metastatic cancer cells. [@JR170005-28] [@JR170005-29]

The role of VWF and its cleaving protease ADAMTS13 in melanoma metastasis is much less clear. While mutation rates in *VWF* are not associated with the long-term outcome in patients with melanoma, its plasma levels or the presence of ultra-large VWF on endothelial surface is shown to be important for the development of thrombosis and tumor metastasis. [@JR170005-12] [@JR170005-13] [@JR170005-30] [@JR170005-31] VWF is highly expressed in the vascular endothelium within the tumor, but not in the malignant melanoma cells themselves ( [Fig. 5](#FI170005-5){ref-type="fig"} and [Table 2](#TB170005-2){ref-type="table"} ). Therefore, VWF may be an important adhesion protein involving in thromboembolism and tumor metastatic process. Consistent with this notion, patients with melanoma had approximately twofold increase in their mean plasma concentrations of VWF antigen compared with the healthy controls (24 vs. 14 μg/mL). [@JR170005-13] The increased levels of plasma VWF correlated with enhanced tumor progression in these patients. [@JR170005-32] Blocking antibodies against VWF appeared to attenuate the binding of tumor cells to platelets by 75 to 81%. [@JR170005-30] Paradoxically, lung colonization by cancer cells was enhanced in the *VWF* -knockout mice [@JR170005-12] and inhibition of platelet glycoprotein Ibα led to significant increase in the formation of pulmonary foci of tumor cells. [@JR170005-33] While the mutation burden in ADAMTS13 is not associated with the long-term outcome in patients with melanoma, reduced ADAMTS13 activity was reported in the tumor microenvironment or vessels, [@JR170005-13] likely resulting from the locally released inflammatory cytokines (TNF-α, IFN-γ, and IL-6), which may inhibit ADAMTS13 synthesis [@JR170005-21] and activity. [@JR170005-34] In seven cases we studied by immunohistochemistry, ADAMTS13 expression varied significantly from negative to strong positive ( [Fig. 5](#FI170005-5){ref-type="fig"} and [Table 2](#TB170005-2){ref-type="table"} ), although proteolytic activity of tissue-derived ADAMTS13 was not determined. Reduced ADAMTS13 activity may result in an accumulation of ultra-large VWF on endothelial surface and heightened platelet adhesion and aggregation, promoting thromboembolism and metastasis.

We conclude that high mutation rates in *FVIII* , but not in *VWF* and *ADAMTS13* , may have a value in predicting a long-term outcome in patients with cutaneous metastatic melanoma. The findings demonstrate a potential role of procoagulant factors in pathobiology of metastatic melanoma, providing a rationale for a novel therapeutic strategy in patients with metastatic melanoma.
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